- Prev close
- $514.99
- Day range
- $508.14 – $525.97
- From 52-wk high
- -8.1%
- Next earnings
- in 41 days
VRTX rose +0.5% in a strong tape, and the move looks benign: the stock is near its 52-week high at $560.25 while the company still shows 10.2% revenue growth and 35.0% net margins.
VRTX
VERTEX PHARMACEUTICALS INC
As of Sep 21, 2026
72/100
Looks healthyHealth ScoreWhy it moved
The primary driver looks market-wide, not stock-specific: VRTX finished +0.5% while the S&P 500 rose +1.6% and the Nasdaq 100 rose +2.8%, so the stock actually lagged the broad rally. There is no same-sector peer move provided here, and the available company news is dated and not tied to a fresh catalyst, so the session reads like a modest participation day rather than a company-specific rerating.
Normal volatility?
Yes — this looks like ordinary volatility for a quality large-cap, not a fundamental break. Revenue is still up 0.5% YoY TTM, the latest quarter is up 0.5% YoY, and EPS is up 0.5% YoY TTM, while margins remain strong at 86.0% gross, 38.0% operating, and 35.0% net. The valuation is not cheap at 29.2 times earnings, 24.0 forward P/E, and a PEG of 2.28 — PEG, or P/E divided by growth, means investors are paying 2.28× the growth rate — so the stock can move on sentiment even when fundamentals stay intact. The beta of 0.29 also points to lower-than-market volatility, which makes a +0.5% session especially unremarkable.
Earnings preview
The next earnings date is not available this period, so I can't anchor a date for the report. The visible fundamentals imply a consensus backdrop of 10.2% revenue growth, 12.4% latest-quarter revenue growth, and 22.5% EPS growth, with 86.0% gross margin, 38.0% operating margin, and 35.0% net margin. The market is likely focused on whether the core cystic fibrosis franchise keeps compounding, how quickly the renal and endocrinology pipeline can add growth beyond CF, and whether the recent $10 billion Crinetics acquisition is starting to broaden the revenue base rather than just adding story value. Prior-earnings reaction data is not provided here.
This report is for informational and educational purposes only. It does not constitute financial, investment, tax, or legal advice. The platform does not recommend buying or selling any security.
Track VRTX with WhyIHold
Get a plain-English explanation the next time VERTEX PHARMACEUTICALS INC makes a big move — so you know whether it's benign or worth your attention.